NPS Going Strong With Gattex
Sales of short bowel syndrome drug Gattex have been strong despite worries over price, says Francois Nader CEO of NPS Pharmaceuticals.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
